Clinical Trial Pipeline - Robust and Promising

The ongoing research pipeline for Non-Invasive Prenatal diagnostics (NIPD) is robust and will help in revealing promising results, says RNCOS.

NOIDA, India (prHWY.com) January 8, 2013 - According to a new research report by RNCOS entitled, "US Non-Invasive Prenatal Diagnostics - Market Insight", the research pipeline for NIPD tests is robust and will help to reveal new avenues. Several Non-invasive Aneuploidy-based studies have been taking place with the primary aim to identify new biomarkers from the pregnant mother without invading the fetus. The research pipeline is being led by companies already in the NIPD business and these companies are trying to carry validation studies for existing products and also lead to new discoveries. Validation studies are majorly being conducted to evaluate the utility of the advanced tests in pregnancies with varying risk of aneuploidies. Amongst the major focus areas are Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, Sex Chromosome Aberrations and other Microdeletions.

The US prenatal diagnostics market is one of the largest and most promising markets for fetal monitoring, diagnostics, and predictive testing. The biggest driver for this market is the limitations posed by the traditional invasive diagnostic technologies, such as CVS and amniocentesis to the health of fetus and mother. The NIPD market is represented by only a few companies such as Sequenom, Verinata and Ariosa diagnostics. One of the promising new market entrants is Natera. With the potential to cater to a high demand population, this sector has high untapped potential and it is expected that it will evolve greatly in the future.

The report, "US Non-Invasive Prenatal Diagnostics - Market Insight", spread in over 55 pages provides an in-depth research and rational analysis of the current status and expected position of the US NIPD Market. It facilitates the future forecasts on the overall US NIPD Market size by 2016 and takes into account pessimistic and optimistic scenarios that could prevail in the market. Moreover, the report projects the potential market to be tapped by currently active market players. It also analyzes the opportunity assessment for companies in the US NIPD Market in terms of leading technologies. In addition it elaborates on the ongoing clinical trials and the various restraints faced by the sector. To provide a holistic view, it also provides a competitive assessment of the major players describing their key business and comparing their strengths and weaknesses.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM450.htm

Some of our Related Reports are:

- US Cardiac Device Market Analysis (http://www.rncos.com/Report/IM441.htm)
- US Clinical Laboratory Testing Market Assessment (http://www.rncos.com/Report/IM442.htm)
- Global Genetic Testing Market Forecast to 2015 (http://www.rncos.com/Report/IM445.htm)
- Indian Diagnostic Services Market Outlook 2015 (http://www.rncos.com/Report/IM418.htm)
- US Nutraceuticals Market Analysis (http://www.rncos.com/Report/IM350.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: us nipd sector

Categories: Health

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code